Description
Research Overview
TIRZ is a synthetic peptide-based dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has been extensively investigated in research involving glucose metabolism, insulin signalling, energy balance and metabolic physiology.
Research Focus
Research has examined TIRZ in relation to GIP and GLP-1 receptor signalling, glucose-dependent insulin secretion, glucagon regulation, gastric emptying, appetite-related signalling and energy intake. Large clinical research programmes have evaluated the compound in people with type 2 diabetes, obesity and related metabolic conditions.
Scientific Context
TIRZ activates two incretin receptor pathways through a single molecular structure. Clinical studies have investigated its effects on glycaemic control, bodyweight and other metabolic parameters, while ongoing research continues to examine its longer-term effects and potential applications across different populations.
Important Research Note
TIRZ has been extensively studied in human clinical trials and has received regulatory approval for specific medical indications in certain jurisdictions. However, this AXEN LABS product is supplied strictly for research purposes. Clinical findings from approved pharmaceutical formulations should not be interpreted as evidence that this research product is suitable for weight management, diabetes treatment, performance enhancement or any other human application.
For research purposes only. Not intended for human or veterinary use.
